Circulating tumor cell detection: A prospective comparison between CellSearch® and RareCyte® platforms in patients with progressive metastatic breast cancer

Home > Science Hub > Circulating tumor cell detection: A prospective comparison between CellSearch® and RareCyte® platforms in patients with progressive metastatic breast cancer
Back to the list

April 12, 2022

Dirix L et al. Breast Cancer Research and Treatments, 2022

Circulating tumor cell detection: A prospective comparison between CellSearch® and RareCyte® platforms in patients with progressive metastatic breast cancer

Circulating tumor cell detection: A prospective comparison between CellSearch® and RareCyte® platforms in patients with progressive metastatic breast cancer

Download Publication

You might also be interested by

Posters

Validation of an ultra-sensitive assay for biomarker testing in NSCLC patients as Clinical Trial Assay (CTA)

March 3, 2026

More info

Posters

Challenging Hybrid Affinity Approach: Streamlined Total Antibody Quantitation with Uncompromised Sensitivity

March 3, 2026

More info

Posters

Patient-Centric Measurement of M-Protein Using High-Resolution Intact Mass Spectrometry

March 3, 2026

More info

Web News

CellCarta Appoints Ehab A. El-Gabry, MD, as Chief Medical Officer & Head of Companion Diagnostics to Advance CDx Strategy, Digital Pathology and AI

March 3, 2026

More info